Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET. (Q35088072)

6 August 2017

1 reference

title

Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET. (English)

1 reference

6 August 2017

main subject

acute coronary syndrome

1 reference

1

David J Moliterno

1 reference

6 August 2017

Albert W Chan

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Journal of the American College of Cardiology

6 August 2017

published in

1 reference

6 August 2017

volume

41

1 reference

6 August 2017

issue

4 Suppl S

1 reference

6 August 2017

page(s)

49S-54S

1 reference

Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Are we mortgaging the medical profession?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

The open-artery theory is alive and well--again

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Advances in the medical management of acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the M

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events i

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Potential non-glycoprotein IIb/IIIa effects of abciximab

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

In-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial infarction (GRAMI trial). Gianturco-Roubin in Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. PASTA Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Clinical and angiographic follow-Up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902835-8

7 January 2021

10.1016/S0735-1097(02)02835-8

Identifiers

DOI

1 reference

6 August 2017

1 reference